Literature DB >> 8259275

Retreatment of full-thickness macular holes persisting after prior vitrectomy. A pilot study.

D Ie1, B M Glaser, J T Thompson, R N Sjaarda, L W Gordon.   

Abstract

PURPOSE: Vitrectomy with fluid-gas exchange has been shown to close more than one half of full-thickness macular holes, with improvement in visual acuity. By adding the appropriate dose of transforming growth factor-beta 2, a higher success rate has been reported. However, there still remain cases of macular holes that fail to close after vitreous surgery. The current pilot study is designed to determine whether reoperation may have a role in the management of cases that fail after vitreous surgery.
METHODS: Twelve eyes with persistent full-thickness macular holes that failed to close after an initial vitrectomy underwent reoperation using 1330 ng transforming growth factor-beta 2.
RESULTS: After the second operation, closure occurred in 12 (100%) of 12 eyes. Follow-up ranged from 8 to 16 months. Visual acuity also improved by two or more lines in 5 (42%) of 12 patients. Increased nuclear sclerosis occurred in nine (90%) of the ten phakic eyes. Of the five eyes showing visual improvement, four required cataract extraction and intraocular lens implantation.
CONCLUSION: Retreatment of persistent full-thickness macular holes with transforming growth factor-beta 2 appears to have a beneficial effect on both neurosensory retinal flattening and visual outcome.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8259275     DOI: 10.1016/s0161-6420(93)31397-7

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  9 in total

1.  Predictive values in macular hole repair.

Authors:  Hans Hoerauf
Journal:  Br J Ophthalmol       Date:  2007-11       Impact factor: 4.638

2.  Retreatment of full-thickness macular hole: predictive value of optical coherence tomography.

Authors:  Jost Hillenkamp; Jürgen Kraus; Carsten Framme; Timothy L Jackson; Johann Roider; Veit-Peter Gabel; Helmut G Sachs
Journal:  Br J Ophthalmol       Date:  2007-05-02       Impact factor: 4.638

3.  Heavy silicone oil (Densiron-68) for the treatment of persistent macular holes: Densiron-68 endotamponade for persistent macular holes.

Authors:  Stanislao Rizzo; Federica Genovesi-Ebert; Andrea Vento; Federica Cresti; Sofia Miniaci; Maria Chiara Romagnoli
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-08-01       Impact factor: 3.117

4.  Natural outcomes of stage 1, 2, 3, and 4 idiopathic macular holes.

Authors:  T Hikichi; A Yoshida; J Akiba; C L Trempe
Journal:  Br J Ophthalmol       Date:  1995-06       Impact factor: 4.638

5.  Surgical management of macular holes: results using gas tamponade alone, or in combination with autologous platelet concentrate, or transforming growth factor beta 2.

Authors:  M Minihan; M Goggin; P E Cleary
Journal:  Br J Ophthalmol       Date:  1997-12       Impact factor: 4.638

6.  The role of patient age and intraocular gases in cataract progression following vitrectomy for macular holes and epiretinal membranes.

Authors:  John T Thompson
Journal:  Trans Am Ophthalmol Soc       Date:  2003

7.  FIRST FAILED MACULAR HOLE SURGERY OR REOPENING OF A PREVIOUSLY CLOSED HOLE: Do We Gain by Reoperating?-A Systematic Review and Meta-analysis.

Authors:  Gerard A Reid; Niamh McDonagh; David M Wright; John T O Yek; Rohan W Essex; Noemi Lois
Journal:  Retina       Date:  2020-01       Impact factor: 3.975

8.  Management of Stage IV Macular Holes: When Standard Surgery Fails.

Authors:  R Reis; N Ferreira; A Meireles
Journal:  Case Rep Ophthalmol       Date:  2012-08-08

9.  Outcomes of Light Silicone Oil Tamponade for Failed Idiopathic Macular Hole Surgery.

Authors:  M Hossein Nowroozzadeh; Hossein Ashraf; Mehdi Zadmehr; Mohsen Farvardin
Journal:  J Ophthalmic Vis Res       Date:  2018 Apr-Jun
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.